Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access for Commercially Out-of-Spec Axicabtagene Ciloleucel in Japan
jRCT2033230370Recruiting
- Sponsor
- Kite Pharma
- Start
- Dec 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 2
01
Overview
Open-label, single-arm trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Kite Pharma. Primary endpoint: Incidence of serious adverse events, deaths, and adverse events of special interest. Started Dec 2023; status: recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2033230370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033230370.